Finasteride and turosteride were selective inhibitors of the type 2 isoform (Ki (type 2) = 7.3 and 21.7 nM compared to Ki (type 1) = 108 and 330 nM, respectively). 4-MA and the lipido-sterol
extract of Serenoa repens (LSESr) markedly inhibited both isozymes (Ki(type1) = 8.4 nM and 7.2 micrograms/ml, respectively; Ki (type 2) = 7.4 nM and 4.9 micrograms/ml, respectively). The three azasteroids were competitive inhibitors vs substrate, whereas LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme.Saw palmetto vs. Proscar on urine flow rate (milliliters per second)
Saw palmetto extract Proscar Initial Measurement 9.53 ml/sec 9.6 ml/sec 3 months 13.15 ml/sec* 10.4 ml/sec 12 months ** 11.2 ml/sec % increase 38% in 3 months 16% in 12 months *Many studies on the Saw palmetto extract were less than 90 days; final measurements were calculated as 90 measurements. **There are no long-term studies on Saw palmetto extract, yet the effect at 3 months (or less) is obviously superior to that of Proscar. Clinical studies demonstrating the efficacy of Saw palmetto* in BPH Authors Type of Study No. ofpatients Length of study Results Boccafoschi, et al Double-blind 22 60 days Significant difference for volume voided, maximum flow, mean flow, dysuria, nocturia Cirillo, et al Open 47 4 months Significant difference for: dysuria, nocturia, urine flow Tripodi, et al Open 40 30-90 days Significant difference for: dysuria, nocturia, volume of prostate, voiding rate, residual urine Emili, et al Double-blind 30 30 days Significant difference for: number of voidings, strangury, maximum and mean urine flow, residual urine Greca, et al Open 14 1 to 2 months Significant difference for: dysuria, perincal heaviness, nocturia, volume of urine per voiding, interval between two dumal voidings, sensation of incomplete voiding Duvia, et al Controlled trial vs. pygeum 30 30 days Significant difference for voiding rate Tasca, et al Double-blind 30 31 to 90 days Significant difference for: frequency, urine flow measurement Cukier, et al Double-blind 168 60 to 90 days Significant difference for: dysuria, frequency, residual urine Crimi, et al Open 32 4 weeks Significant difference for: dysuria, nocturia, flow measurement, residual urine Champault, et al Double-blind 110 28 days Significant difference for: dysuria, nocturia, flow measurement, residual urine Mattei, et al Double-blind 40 3 months Significant difference: dysuria, noctu
extract of Serenoa repens (LSESr) markedly inhibited both isozymes (Ki(type1) = 8.4 nM and 7.2 micrograms/ml, respectively; Ki (type 2) = 7.4 nM and 4.9 micrograms/ml, respectively). The three azasteroids were competitive inhibitors vs substrate, whereas LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme.Saw palmetto vs. Proscar on urine flow rate (milliliters per second)
Saw palmetto extract Proscar Initial Measurement 9.53 ml/sec 9.6 ml/sec 3 months 13.15 ml/sec* 10.4 ml/sec 12 months ** 11.2 ml/sec % increase 38% in 3 months 16% in 12 months *Many studies on the Saw palmetto extract were less than 90 days; final measurements were calculated as 90 measurements. **There are no long-term studies on Saw palmetto extract, yet the effect at 3 months (or less) is obviously superior to that of Proscar. Clinical studies demonstrating the efficacy of Saw palmetto* in BPH Authors Type of Study No. ofpatients Length of study Results Boccafoschi, et al Double-blind 22 60 days Significant difference for volume voided, maximum flow, mean flow, dysuria, nocturia Cirillo, et al Open 47 4 months Significant difference for: dysuria, nocturia, urine flow Tripodi, et al Open 40 30-90 days Significant difference for: dysuria, nocturia, volume of prostate, voiding rate, residual urine Emili, et al Double-blind 30 30 days Significant difference for: number of voidings, strangury, maximum and mean urine flow, residual urine Greca, et al Open 14 1 to 2 months Significant difference for: dysuria, perincal heaviness, nocturia, volume of urine per voiding, interval between two dumal voidings, sensation of incomplete voiding Duvia, et al Controlled trial vs. pygeum 30 30 days Significant difference for voiding rate Tasca, et al Double-blind 30 31 to 90 days Significant difference for: frequency, urine flow measurement Cukier, et al Double-blind 168 60 to 90 days Significant difference for: dysuria, frequency, residual urine Crimi, et al Open 32 4 weeks Significant difference for: dysuria, nocturia, flow measurement, residual urine Champault, et al Double-blind 110 28 days Significant difference for: dysuria, nocturia, flow measurement, residual urine Mattei, et al Double-blind 40 3 months Significant difference: dysuria, noctu
] 